TWD
PLX icon

True Wealth Design’s Protalix BioTherapeutics PLX Stock Holding History

True Wealth Design’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268 Buy
115
+104
+945% +$220 ﹤0.01% 2387
2026
Q1 		$24 Buy
+11
New +$27 ﹤0.01% 2633

Other funds holding PLX

OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design's PLX Position: Q2 2026 in Review

True Wealth Design increased its Protalix BioTherapeutics (PLX) stake by 945% in Q2 2026, buying an estimated $220 and bringing the position to 115 shares worth $268. The position accounts for ﹤0.01% of the portfolio, ranked #2387.

True Wealth Design first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • True Wealth Design held 115 shares of Protalix BioTherapeutics worth $268 as of Q2 2026.
  • True Wealth Design bought 104 Protalix BioTherapeutics shares in Q2 2026, an estimated $220.
  • Protalix BioTherapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2387 holding.
  • True Wealth Design first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 5 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.